Formedium’s products, including Raffinose and Glucose, mentioned in Nucleic Acids Research

Formedium’s products have been mentioned in the following article: Structural basis for binding the TREX2 complex to nuclear pores, GAL1 localisation and mRNA export. The research was carried out by Divang Jani; Eugine Valkov; Murray Stewart,  and was featured on the Oxford Academic website.

The following is a snippet from the report:

Yeast growth media

Selection of URA3+ strains was performed on SD–Adenine–Uracil plates. Following verification of strains (see above), cells were grown in SD–Adenine (to maintain selection of the pASZ11:NupNop plasmid) for all experiments. SD–Adenine (pH 5.8) was formulated as follows (quantities of components per L are indicated): Yeast nitrogen base without amino acids (Formedium, Hunstanton, UK), 6.7 g; D(+) glucose, D(+) raffinose or D(+) galactose (Formedium, Hunstanton, UK), 20 g; Bacto-agar (for plates; Becton Dickinson and Co., MD, USA), 20 g; L-Isoleucine, 30 mg; L-Valine, 150 mg; L-Arginine-HCl, 20 mg; L-Histidine-HCl monohydrate, 20 mg; L-Leucine, 100 mg; L-Lysine-HCl, 30 mg; L-Methionine, 20 mg; L-Phenylalanine, 50 mg; L-Threonine, 200 mg; L-Tryptophan, 20 mg; L-Tyrosine, 30 mg; L-Glutamic acid, 20 mg; L-Aspartic acid, 20 mg; L-Serine, 100 mg and Uracil, 20 mg.

View the complete report >


We are most grateful to Birthe Meineke for invaluable assistance with molecular biology and to our colleagues, especially Nick Barry, Jon Howe, Yohei Ohashi, Lyudmila Dimitrova, Chris Johnson and Neil Marshall for their assistance and advice. We thank Olivier Gadal for kindly providing yeast strain YGC242.


Medical Research Council [U105178939 to M.S.]; Wellcome Trust [Programme Grant 080522 to M.S.].

Conflict of interest statement. None declared.

For references, please view the full report.